WASHINGTON — President Donald Trump has stopped talking about the decades-old antimalarial drug he once touted as a “game changer” for COVID-19, but it won’t be as simple for the rest of the health system to just move on.
When Trump first began touting the drug in mid-March, a frenzy ensued as hospitals, patients and doctors raced to secure supplies. Many believed even if the drug didn’t turn out to be an effective coronavirus treatment, it might be able to ward off infection.
But as quickly as pharmacies were drained of the pills, the tide has now turned against hydroxychloroquine and its chemical cousin, chloroquine. Regulators and scientists have raised concerns about potentially serious side effects, while Gilead Sciences Inc.’s antiviral therapy remdesivir was cleared for U.S. use. Some hospitals, including Mount Sinai Health System in New York, no longer include the drug in their treatment regimen for COVID-19.
Stay connected to the stories and events that make your community a special place to call home.
Subscriptions start at $14.90/month.View subscription options
- Unmatched coverage of Allen County’s local news and sports, a tradition dating back to 1867
- Compelling portraits of our residents, experienced reporting and thoughtful analysis
- Unlimited online access to iolaregister.com and our archives